GRAIL (NASDAQ:GRAL – Get Free Report) and Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.
Profitability
This table compares GRAIL and Kalaris Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GRAIL | -236.95% | -15.88% | -14.02% |
| Kalaris Therapeutics | N/A | -71.71% | -42.95% |
Insider and Institutional Ownership
66.0% of Kalaris Therapeutics shares are owned by institutional investors. 1.8% of GRAIL shares are owned by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GRAIL | $147.17 million | 24.09 | -$408.35 million | ($9.75) | -8.14 |
| Kalaris Therapeutics | N/A | N/A | -$43.44 million | ($2.02) | -2.00 |
Kalaris Therapeutics has lower revenue, but higher earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for GRAIL and Kalaris Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GRAIL | 1 | 5 | 4 | 0 | 2.30 |
| Kalaris Therapeutics | 1 | 0 | 6 | 1 | 2.88 |
GRAIL presently has a consensus target price of $67.78, indicating a potential downside of 14.61%. Kalaris Therapeutics has a consensus target price of $18.75, indicating a potential upside of 364.11%. Given Kalaris Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than GRAIL.
Risk & Volatility
GRAIL has a beta of 3.24, meaning that its share price is 224% more volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500.
Summary
Kalaris Therapeutics beats GRAIL on 10 of the 14 factors compared between the two stocks.
About GRAIL
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.
About Kalaris Therapeutics
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Receive News & Ratings for GRAIL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRAIL and related companies with MarketBeat.com's FREE daily email newsletter.
